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ABSRACT 
Objectives: The objective of this study is to determine how patient and physician level 
factors influence decisions to prescribe atypical antipsychotics to children (under 18years) 
diagnosed with mental health disorders. 
Methods: This study is a cross-sectional survey of general practitioners and 
psychiatrists. A web-based patient simulation survey using fractional factorial design was 
administered with the help of a commercial vendor. Respondents were presented with simulated 
patient profiles that contained various levels of factors hypothesized to be important in decision 
making. Physician treatment decisions were measured along with demographics and beliefs 
about available products. Marginal modelling using general estimating equations was used for 
analysis. 
Results: Patient age, disease severity, physician specialty and beliefs about evidence 
supporting use of the drug were found to significantly influence physician prescribing decisions. 
Conclusions: This study shows the factors important to decision making for physicians 
from different specialties and can help improve clinically appropriate and safe use of 
antipsychotics. 
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INTRODUCTION 
Atypical antipsychotics (AP) have been in the market since Clozapine was introduced in 1989 
(Malone, Sheikh & Zito, 1999). They were approved by the United States Food and Drug Administration 
(FDA) in adults for mood disorders at the time of release and gained a lot of popularity because they 
possessed the effect of conventional antipsychotics while not causing severe extra pyramidal side-effects 
such as akasthisia, parkinsonism, dystonia and tardive dyskinesia (Pathak, West, Martin, Helm & 
Henderson, 2010). This factor helped spur a phenomenal increase in their use in adults, as well as in 
children. Since then, many other APs, such as ziprasidone, olanzapine, aripiprazole, paliperidone, have 
also been approved by the FDA. Their use in children had been of particular concern since there were no 
clinical trials supporting such use at the time (Malone, Sheikh & Zito, 1999).
The newer APs have been approved for use in diseases such as schizophrenia and bipolar disorder 
(Pathak et al, 2010). The use of these drugs for the treatment of conduct disorder, hyperactivity disorder, 
Attention Deficit Hyperactivity Disorder (ADHD), Tourette’s syndrome, has not been approved yet due 
to the lack of evidence supporting such use. However, this unapproved use, or ‘off-label use’, as it is 
called, is well known and quite common. Despite the lack of evidence, FDA does not restrict use of drugs 
for unapproved indications. In fact the FDA has stated that it does not, in any way, limit the manner in 
which the physician chooses to use a drug (Texas Department of Family and Protective Services, 2010). 
A research study highlights that APs are prescribed outside their indication about 70% of the time (Farah, 
2005). Staller, Wade & Baker (2005) found that 77% of APs are used in youth who do not even have a 
psychotic disorder. Research shows that the number of children covered by Medicaid using APs has 
doubled from 2001 to 2005 (Pathak et al, 2010). Use in children under 18 years has accounted for 15% of 
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total use of antipsychotics in 2004 - 2005. This number was as low as 7% back in 1996 – 1997 (Domino 
& Swartz, 2008). Further study reveals that among children, foster children use more psychotropic 
medications in general than non-foster children. Foster children account for only 3% of the population of 
Medicaid children, but they use almost 9 times as many antipsychotics as the non-foster children (Crystal, 
Olfson, Huang, Pincus & Gerhard, 2009).  
There is limited evidence studying the effects of these drugs in children, but most existing studies 
point towards a range of serious adverse events such as weight gain, diabetes, hypertension, metabolic 
and endocrine abnormalities, hyperprolactinemia and dyslipidemia in the short term and several other 
unknown long-term effects (Vitiello et al., 2009; McIntyre & Jerrell, 2008; Federowicz & Fombonne, 
2005; Kumra et al., 2008). With increasing budgetary constraints, payers such as Medicaid have sought to 
better understand the use of these drugs in children (Surles, 2005). This has made the ‘off-label’ 
prescribing of APs in children and adolescents, between the ages of 4 to 17 years, a major area of 
concern. 
In 2011, a Government Accountability Office (GAO) study examined the rates of use of 
psychotropic medication among foster children in several states and recommended to the Department of 
Health and Human Services that they should provide guidance to states on best practices for overseeing 
psychiatric prescriptions (Kutz, 2011). In response to this, the Department of Health and Human Services 
sent a letter to the state Medicaid directors making them aware of the results of the GAO study that 
provides evidence towards the growing problem of safe, appropriate and effective use of psychiatric 
prescriptions among foster children. They proposed an expansion of activities and collaboration between 
the Administration for Children and Families (ACF), The Center for Medicare and Medicaid Services 
(CMS) and the Substance Abuse and Mental Health Services Administration (SAMHSA). This includes 
expansion of online resources and webinars, development of quality measures to evaluate states, working 
with states to enhance Drug Utilization Review, building Health Homes, encouraging use of Health 
Information Technology and development of guidelines for the use of psychiatric medications in children 
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and adolescents along with the American Academy of Child and Adolescent Psychiatry (AACAP) 
(DHHS, personal communication, November 23, 2011). 
The increasing recognition from the FDA and the Department of Health and Human Services 
demonstrates the importance of addressing the issue of use of APs in children. The guidelines to be issued 
by SAMHSA and the AACAP dealing with appropriate use of APs in children hold the potential to 
revolutionize today’s antipsychotics market. This study aims to help understand the process of 
prescription decisions better so all of the players in the health care system can plan for better ways to 
assure more efficient and safer use of APs in children and adolescents. The objective of the study is to 
find the patient and physician level factors that influence the physician’s decision to prescribe APs in 
children and adolescents for various indications
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.LITERATURE REVIEW 
Physician prescription decisions 
Several researchers have compared prescription decisions to an art that goes beyond mere 
pharmacological factors. It has been called a complex skill that requires the physician to carefully 
evaluate the patient’s physical, psychological, social and behavioral illnesses and weigh the benefits and 
risks of each treatment alternative and comparing it to the option of not treating the indication (Howie, 
1976).
There is also a lot of evidence to suggest that prescription decision making is not dependent only 
upon clinical factors. In his study on antibiotic use in cases of sore throat, Howie demonstrated that 
psychological, behavioral and social information about the patient can substantially influence prescription 
decisions (Howie, 1976). Harris (1980) goes a little further to suggest that when the decision making is in 
an area that is recognized as ‘pharmacologically dubious’, social factors influence prescribing. Bradley 
(1992a) made several attempts to identify the factors causing ‘uncomfortable prescribing decisions’ 
among physicians to better understand the psychological decision making process. 
In an experimental study conducted in Peru to understand the factors influencing prescribing 
behavior in treatment of childhood diarrhea, it was found that while physicians seemed to possess 
adequate knowledge about conditions under which antibiotics are required in childhood diarrhea, their 
prescribing patterns did not appear to match their clinical beliefs. The article concluded that knowledge 
about disease seems to make very little difference as to what the physician prescribes. They describe the 
decision making process as social and not logical. The researchers further narrowed down the social 
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factors to a few important ones such as the physician’s role as a socially defined good practitioner, 
previous experiences with diarrhea cases and sometimes even deficiencies in knowledge. A few other 
factors such as the physician’s length of practice, perception of the family’s expectations also seemed to 
influence prescribing behavior (Paredes, De La Pena, Flores-Guerra, Diaz & Trostle, 1996). 
In another study similarly aimed at understanding prescribing decisions, researchers found that 
the physicians’ perceptions of patients’ expectations seemed to influence prescribing behavior the most. 
Other factors such as the patient’s age, ethnic group and symptoms also influence prescribing behavior. 
The physician’s perception of the patient’s expectations in turn seemed to depend on the patient’s 
symptoms, complaints, age and even on the doctor’s own qualifications. The study essentially pointed out 
the importance of patient variables in determining what is prescribed to patients (Britten & Ukomunne, 
1997). 
Bradley (1992b) narrowed down the list of factors influencing the decision of whether or not to 
prescribe into three general categories: Patient factors, physician factors and physician concern about 
drugs or product factors. After several interviews conducted across North England, he concludes that 
“age, ethnicity, social class, education, doctor’s prior knowledge of patients, doctor’s feeling toward the 
patient, communication problems and the doctor’s desire to try to preserve the doctor-patient relationship” 
are the important patient factors; “factors relating to doctor’s role perception and expectation of 
themselves, uncertainty, peer influences, logistic factors and the experience of medical or therapeutic 
misadventures” are the important physician factors; and the doctor’s concerns about drugs, or product 
factors as it can also be called, include the drug’s “side-effects, cost, risk of dependence, necessity, 
antibiotic resistance, efficacy” etc., in the order of their importance. 
Prescribing of atypical antipsychotics 
A thorough search of the literature in the field of antipsychotics research provides insight into the 
use of APs. Cooper et al. (2006) studied the trends in prescribing of antipsychotic medications in children. 
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They examined the diagnoses that were associated with the use of APs and found that nearly 29% of the 
use was for ADHD and conduct disorder, which was not a labeled use of the products. Bipolar disorder 
accounted for 23% of use, followed by 13.8% for non-psychiatric disorders. Schizophrenia, for which 
APs are FDA approved for use in children, could be attributed to only 13.5% of the use. The use of these 
drugs for approved indications grew 2.49 times between the periods 1995-1998 and 1999-2002, while the 
use for the unapproved indications grew by 3.52 times. Interestingly the article also concluded that 30% 
of all antipsychotic prescriptions were attributable to non-psychiatrists. The fact that there was a three-
fold increase in the use of APs by non-mental health providers during the study period demonstrates the 
importance of studying use not just among mental health providers, but also among primary care 
physicians. 
Many researchers studying the trends and patterns of use of these APs have concluded that 
several different factors seem to drive use. In accordance with the prescribing decision making literature, 
most of these factors seem to involve social information of the patient. Olfson et al. (2006) found that 
males seem to be receiving more APs than females. And that Medicaid insured children also are 
prescribed more of these than are privately insured children. While the reasons for this differential use 
have not been established by research, many of these patterns have been documented by several 
researchers (Olfson et al., 2006; Hamann, Langer, Leucht, Busch & Kissling, 2004; DHHS, personal 
communication, November 23, 2011).  
Research points out that the differential use among various APs that exists in the market is not 
completely evidence based (Pathak et al., 2010). Cullen et al. (2008) attempted to analyze evidence from 
various open trials comparing the second generation antipsychotics head-to-head in order to establish a 
reason for the differential use of the products. However, because very little comparative efficacy data 
exists, they concluded that the physician’s choice of APs depends more on the side-effect profile of each 
drug. The adverse effects profile for these antipsychotics has been well studied in adults, but large clinical 
trials or long-term studies do not exist in children and adolescents. Evidence available from an expert 
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panel convened by the European Neuro-psychopharmacology to study efficacy and safety data states that 
children and adolescents are more vulnerable to these side-effects than adults (Vitiello et al., 2009). 
The patient factors influencing prescribing of APs seem to include not just their diagnoses, age 
and gender but even some risk factors that can make them susceptible to the side-effects of these drugs. 
McIntyre and Jerrell (2008), studying the pattern of adverse events associated with the use of 
antipsychotics in children and adolescents in the South Carolina Medicaid database, found that not only 
do children treated with these drugs have the risk of acquiring diseases such as obesity, type II diabetes, 
dyslipidemia and orthostatic hypotension among others, but certain criteria seemed to make them more 
vulnerable to these adverse events than others. For example, the authors concluded, patients with 
substance abuse disorders are at a greater risk to cardiovascular events. They also found that adolescents 
over 13 years old can be more vulnerable to developing type II diabetes and that girls are more likely than 
boys to develop obesity, type II diabetes, orthostatic hypotension and dyslipidemia (McIntyre & Jerrell, 
2008). On the contrary, a meta-analysis of randomized clinical trials, looking at the safety and tolerability 
of APs in children concludes that males are more susceptible to weight gain than females. They also list 
parental body mass index (BMI) and low initial BMI as other risk factors for weight gain (Federowicz & 
Fombonne, 2005). The evidence available is mostly restricted to the short-term and as yet, still 
inconclusive. 
Study significance 
Even though the evidence available as of today is inconclusive, the results of these studies 
suggest that the adverse events caused by APs in children are not only significant, but also differential, 
thereby varying in effect because of the presence or absence of several risk factors. These differential 
adverse event profiles and risk factors may also influence the physician’s prescription choice.  
The letter sent to the state directors from the Department of Health and Human Services mentions 
that factors such as age, gender, behavioral concerns and placement type (for foster children) can affect 
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likelihood of being prescribed psychotropic medications (DHHS, personal communication, November 23, 
2011). A study in Germany trying to decipher medical decision making in antipsychotic drug choice 
concludes that younger physicians are more likely to prescribe second generation antipsychotics than 
older or more experienced physicians (Hamann et al., 2004).  
Evidence from widely varying sources point to several different potential predictors of a 
physician’s choice to treat children and adolescents with APs. These predictors range from patient level 
factors, such as age, insurance, consent from parents; to physician level factors, such as type and size of 
practice, specialization and the propensity to adopt new practices; and even product factors such labeling 
status. 
This study tries to measure the effect of each of physician and patient factors on the physician’s 
decision to prescribe APs in children and adolescents. Based on the evidence presented above, the 
following objectives have been proposed for the study
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RESEARCH OBJECTIVES 
1. To determine how patient level factors, such as age, race, sex or attitude about consent from 
parent/guardian influence the physician’s decision to prescribe atypical antipsychotics in children. 
2. To determine how physician characteristics, such as specialization, mental health patient volume 
or beliefs about drugs influence physician’s decision to prescribe atypical antipsychotics in 
children. 
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METHODS 
Study design 
A cross-sectional patient simulation survey with a fractional factorial design for patient attributes 
was selected as the best approach for addressing the research objectives in a manner that would be as 
unbiased as possible. 
Sample 
The study employed a cross-sectional survey of psychiatrists and primary care physicians.  A 
national sample of physicians was used so as to minimize regional bias and to maximize generalizability 
of results.  The sampling frame included actively practicing primary care physicians and psychiatrists. In 
order to obtain a sufficient number of responses from both groups of respondents, stratified quota 
sampling was used. Two quotas were defined for the purposes of quota sampling. The first quota, 
psychiatrists (PSYCHs), was comprised of psychiatrists treating children and adolescents. The second 
quota, Primary Care Practitioners (PCPs), included family practice, internal medicine, pediatrician and 
general practice physicians treating children and adolescents for mental health problems..  
In order to be eligible for the study, physicians were required to be engaged in full time active 
practice for at least 2 years post-residency. Further, physicians in the PCP quota were required to spend at 
least 50% of their time in outpatient care and those in the PSYCH quota were required to spend at least 
25% of their time in outpatient care. Respondents were also required to have a non-zero percent of patient 
population under 18 years of age, diagnosed with psychosis and currently taking APs.  
 
 
16 
 
Sample collection  
The sample was obtained through a national physician panel maintained and verified by Reckner 
Healthcare. Physicians invited to participate in the study had to go through a set of screener questions to 
determine if they were eligible for the study and to determine which quota they were in. Respondents not 
classified into either of the two quotas or who did not meet the criteria of any of the screening questions 
were terminated from the survey and thanked for their willingness to participate. Eligible respondents 
who completed the survey were promised a summary of the study results as an incentive for participation. 
No monetary incentive was provided.  Physicians were informed that the survey was being conducted for 
researchers at the University of Mississippi and the study had been approved by the University of 
Mississippi Institutional Review Board in order to stress the non-biased nature of the study. The 
anonymity of the survey results was also stressed. 
Data was collected through an on-line survey.  Reckner Healthcare provided survey 
programming, subject recruiting and data collection.  The vendor contacted potential respondents by e-
mail, collected responses and provided the researcher a de-identified data set for analysis. Follow-up 
mailing of summary report to respondents was conducted by the vendor. 
Survey design 
A patient simulation survey aims to collect data from physicians by replicating their daily work 
environment. This technique minimizes response bias by simulating patients that a physician would 
potentially see in a day-to-day practice and recording the treatment decisions made for each patient. To 
simulate patients accurately, all information that a physician will review before treating a patient and all 
treatment options have to be provided to respondents. The information has to not only be complete 
enough, but also presented in a manner that simulates the way information of this nature would appear in 
a typical patient chart.   
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The survey took approximately 15-20 minutes to complete.  The following parts of the survey 
were presented to the physician as part of the research study: 
1. Screener: A short set of screening questions to determine that the respondents met the criteria 
required in the study. The specific criteria that respondents needed to meet were described in the 
previous section. The screener also included some questions about physician practice 
characteristics. Variables measured in this section included years spent in active practice post-
residency, mental health patient volume in a typical week, proportion of patient population less 
than or equal to 18 years of age, proportion of patient population diagnosed with each of 
psychosis, bipolar disorder, conduct disorder and autism, proportion of patient population 
comprised of children less than 18 years of age in foster care and proportion of patient population 
currently taking APs. 
2. Patient simulation: Each physician was presented 10 patient profiles, one at a time. All profiles 
presented a diagnosis of mild, moderate or severe psychosis. The other patient variables such as 
age, parental concern about use of APs, lab values such as WBC count, ANC count were varied 
between the profiles in an orthogonal manner. At the bottom of each patient profile, the physician 
was asked to indicate his/her treatment choice(s) by checking items from a list that included all 
APs available on the market along with the option for using other classes of products, non-
pharmacological treatments and referral to other providers. The patient characteristics provided in 
each profile and the different levels of each characteristic are presented in Table 1. A sample 
patient profile in the format presented to respondents is included in Appendix A. 
3. Follow-up questions:  A few follow-up questions were asked to address key beliefs about the 
level of evidence for use of AP products.  The Evidence Based Practice Attitude Scale (EBPAS) 
was administered to the respondents as part of the follow-up questions to assess physician’s 
adoption of evidence in their treatment decisions and practice. Physician’s beliefs in evidence 
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supporting use of APs in children, less than 17 years of age, diagnosed with psychosis was also 
measured.  
4. Physician background: In this final section, physician demographics were measured. Variables 
collected were age, race and gender.  
Patient profile development  
Development of appropriate patient profiles is an integral part of a patient simulation study. 
Patient profiles were designed to contain the information needed by physicians in order to make treatment 
decisions.  An initial list of patient attributes that were believed to influence the use of APs was 
developed from current literature (see chapter 1). The overall goal was to ensure that the combinations of 
various levels of the patient attributes were composed in a manner that allowed for statistical analysis of 
the effect of each attribute independently. This was achieved by developing an orthogonal fractional 
design using the final attributes. 
Initially the aim of the study was to assess the prescribing pattern of physicians for children with 
any mental health disorders, it was decided that a particular diagnosis has to be identified in order to 
effectively carry out the patient simulation. For this purpose, diagnoses such as psychosis, schizophrenia, 
autism, ADHD and conduct disorder were considered. However, many of these disorders are hard to 
diagnose in a patient in a single interaction and difficult to effectively operationalize in a patient profile. 
Hence, for the sake of a clear and unambiguous description of diagnosis and symptoms, it was decided 
that psychosis will be used for all patient profiles. 
A number of expert interviews were conducted to continuously improve the patient attribute list 
and the presentation in patient profiles. Experienced pediatricians, psychiatrists and pharmacists 
specializing in mental health were identified and interviewed face-to-face or via teleconference in order to 
obtain their input. Three major points of information were gathered from each interview. First, whether 
the list of patient attributes was complete or if it contained any variables that the physician is not 
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accustomed to having available during a regular patient visit; second, the most appropriate manner in 
which the selected attributes could be expressed in text form in a patient profile so that they convey the 
change in level that is intended; and finally, the ideal arrangement of these attributes on the profile so that 
and the information is presented in a customary manner and the respondent is not biased to pay more 
attention to any one attribute than normally would occur. It was also ascertained that none of the attributes 
or their levels were so extreme that the focus of the patient interaction be diverted away from the initial 
diagnosis of psychosis. Interviewees were sent copies of the patient profiles and the survey to go through 
during the development interviews.  
Once the list of patient attributes was finalized, the coded levels of each attribute was then 
expressed in an appropriate text format.  Depending on the patient attribute and how the information 
might typically be presented in a patient chart, each attribute was presented as a bullet point of 
information in a table or as sentences below the table. The final placement of each of these attributes can 
be seen in a sample patient profile provided in Appendix A. The attribute levels for the patients were 
stored in a grid in an Excel spreadsheet.  The text expressions of the attributes were created in another 
worksheet using formulas.  The patient profiles used in the survey were generated through the on-line 
program in a manner similar to that used by mail merge in Microsoft Word, where the text expressions 
were inserted into a patient chart template. 
Profile set 
SPSS Orthoplan procedure was used to create an orthogonal combination of levels of attributes to 
form a set of patients.  The orthoplan procedure combines various levels of attributes to produce a set that 
allows the effect of each variable to be assessed independently during statistical analysis. This procedure 
produced a set of 27 patient profiles. In order to partition the profiles into equal numbered subsets, 3 hold-
out samples were generated to obtain 30 complete patient profiles. 
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Because the respondent population was particularly susceptible to survey fatigue and time 
constraints, it was decided that displaying all 30 profiles to each respondent would be overly burdensome. 
Therefore, the 30 profiles were grouped into 3 subsets of 10 profiles each that were balanced with respect 
to the hypothesized major drivers of use. Each respondent was shown one subset.  The subsets were 
rotated within each quota group such that each subset was used approximately the same number of times 
and each patient profile was shown approximately the same number of times within each physician 
specialty. 
 
Operationalization 
 Patient factors/attributes: All patient factors were manipulated in the patient profiles displayed to 
the respondent. A patient name, selected to match patient race and sex, was presented at the top of every 
profile along with information about the diagnosis of psychosis. The variable foster status (Pt_caregiver) 
was operationalized as whether consent for use of APs was provided by the patient’s ‘parent’ or 
‘guardian’. Profiles presented with the word ‘guardian’ were considered to be foster children. The 
variable concern about consent (Pt_consent) was operationalized as the level of concern expressed by the 
caregiver (parent/guardian) while giving consent for use of APs. This was operationalized as ‘…hasn’t 
expressed any concerns about the use of antipsychotics’ or ‘…has expressed some concern about the use 
of anti-psychotics” or ‘…has expressed a lot of concern about the use of anti-psychotics’ depending on 
the level of the variable. Patient adherence (Pt_adherence) was expressed as whether the caregiver 
mentions that ‘…the patient takes his medications on time’ or ‘…the patient refuses to take medications’. 
Alcohol or substance abuse (Pt_Alc) was expressed as either ‘The patient has no history of alcohol abuse’ 
or ‘The patient has a history of alcohol abuse’. The clinical factors were all expressed in a table 
underneath the patient name and diagnosis. Patient WBC count (Pt_WBC) was expressed as being normal 
or low. The actual numbers, 4150 for low and 7300 for normal, were also used to allow the physician to 
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use their own judgment. Patient ANC count (Pt_ANC) was operationalized in similar to WBC count. The 
count value of 1300 was used for low and 3900 was used for normal levels. Patient’s blood glucose level 
(Pt_diabetes) was also operationalized similarly. The low glucose level was expressed as 85mg/dl and the 
normal level was expressed as 112mg/dl.  
Patient age (Pt_age) was operationalized to be in one of three categories: 5 years and below (4 
years), 6 to 12 years (10 years) and 13 to 17 years (15 years). Values of age were not varied within each 
group so as to minimize variance to obtain more robust results. Patient race (Pt_race) was operationalized 
as either Caucasian or African-American. Patient sex (Pt_sex) was expressed as male or female. Patient 
puberty (Pt_puberty) was expressed as ‘pubertal’ or ‘pre-pubertal’. All of the above variables were 
mentioned in text clearly in the table below the patient name and diagnosis. Patient BMI (Pt_BMI) was 
operationalized as being underweight, normal or overweight. The actual numerical values for BMI were 
obtained from CDC growth charts. Average height of children for the ages of 4 years, 10 years and 15 
years for males and females were also obtained from CDC growth charts. With numerical values for BMI 
and height, weight was computed and all three variables, height, weight and BMI, along with the 
description of overweight, normal or underweight, were displayed in the table clearly.  
Disease severity, with the levels mild, moderate and severe, was expressed both directly at the top 
of the profile with the diagnosis and again with a description of symptoms directly below the diagnosis. 
Symptoms used were common for patients of all age groups, so that variability could be minimized 
during analysis. The set of symptoms used for mild severity were ‘occasional uncontrollable agitation, 
minimally intrusive auditory hallucinations and mild lack of age-appropriate grooming’. For moderate 
severity, the symptom set ‘constant uncontrollable agitation, moderately intrusive auditory hallucinations, 
moderate lack of age-appropriate grooming’ was used and ‘constant uncontrollable agitation, severely 
intrusive auditory hallucinations, severe lack of age-appropriate grooming & some self-harm and harm to 
others’ was used for the severe patients.  
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Physician factors/attributes: The measurement of various physician factors was done through 
questions that can be seen in Appendix B. Physician specialty is classified as either PCP or PSYCH and 
the operationalization is mentioned in the previous section under ‘sample’. Years in active practice, 
mental health patient volume in a typical week, proportion of mental health patient population less 18 
years of age in foster care and past use of APs are assessed as self-reported measures in the screener. 
Similarly, physician age, race and gender were also assessed in the final demographics section of the 
survey.  
The evidence based practice measure was assessed through administration of the Evidence Based 
Practice Attitude Scale (EBPAS) (Aarons, 2004). The EBPAS is a rather recently developed scale. 
However, it has been well validated and cited several times in recent years. The scale was used as 
mentioned by original authors (Aarons, 2004) with all the subscales. 
Physician’s belief regarding the evidence supporting use of APs in children with mental health 
disorders was assessed independently through question Q12 (see survey). Response options provided for 
evidence were (1) labeled indication, (2) medically accepted use but not a labeled indication, (3) no 
evidence supporting use, (4) no evidence supporting use. The response option ‘don’t know’ was recoded 
to ‘no evidence supporting use’ after the data collection phase. Because evidence varies depending up on 
the product being used and the age of the patient, it was assessed independently for all 11 APs, in each of 
three age categories: 5 years and under, 6 to 12 years and 13 to 17 years. During analysis, the maximum 
level of evidence selected by each individual physician for patients in a particular age group was then 
used as the level of evidence variable for patient profiles of the corresponding age. This operationalization 
assumes a class effect for the use of AP products in each age group.    
Dependent variable: The dependent variable in this study is whether an AP product was 
prescribed or not. At the end of each profile the respondent was provided an exhaustive list of treatment 
options. The list of these options can be seen in Appendix A. If the respondent picked any of the AP 
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products for a given profile, the dependent variable was coded as ‘1’, indicating that APs were prescribed 
in that scenario
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DATA ANALYSIS 
The data collected from the survey were analyzed using IBM SPSS (Chicago, Illinois). Data were 
obtained in the form of an SPSS dataset with respondent ID and responses collected from the each 
respondent. There were no missing variables since respondents were required to answer all questions in 
the survey. To ensure data quality, the data were thoroughly vetted qualitatively to make sure responses 
were all answered carefully and responsibly. It was found that some responses included more treatment 
options than would be considered possible in a real world setting. In order to clean the dataset, responses 
with more than three non-AP drugs in two or more patient profiles were deleted. 
 
A regression model was used to meet the research objectives. Since the dependent variable for the study is 
dichotomous (use/no use of APs) a logistic regression model with a logit link function was determined to 
be appropriate. However, the structure of the data obtained was such that each physician treated 10 patient 
profiles. So the treatment decisions made by a given physician were all correlated with each other. 
Therefore, the data in question do not meet the assumption of independence of observations, which is 
required to obtain robust results from a logistic regression model. To account for this lack of correlation, 
marginal modelling using General Estimating Equations (GEE) was employed.  
A GEE model takes into account the correlation between responses from the same respondent by treating 
this correlation as a nuisance variable that can be accounted for during analysis. The correlation matrix 
was assumed to be ‘exchangeable’, meaning that the correlation between all the responses from the same 
respondent was assumed to be equal. Because the dependent variable was binomial, a logit link function 
was used for analysis.              
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Data management 
In order to use a GEE approach, the data needed to be arranged such that SPSS could distinguish the 
within-subject variables from the between subject variables. The dataset obtained from the vendor was in 
wide file format with each individual respondent as a single row with all 10 treatment decisions in 
consecutive columns. This form of data structure was not suitable for running a GEE model. Therefore, 
the dataset was transposed to a long file format where each respondent had 10 separate observations or 
rows, with each row containing the treatment decisions for a single patient profile. The patient profiles 
displayed to each physician were identified by a profile ID assigned to each combination of attributes 
decided earlier. The levels of each attribute were then obtained from the Excel worksheet that was used to 
generate the profiles and then merged with the SPSS dataset to make the final dataset that was ready for 
analysis. To summarize, the final dataset contained 10 observations or rows for each physician. Each of 
the 10 rows contained the same physician demographics and practice characteristic. Each row also 
included a patient profile ID and its corresponding attribute levels and the treatment decision(s) made by 
the physician for that profile. 
Data analysis 
Since sample size obtained was small, a model building approach was chosen to measure the effects of 
each variable. (Hosmer & Lemeshow, 2004). All patient and physician variables were entered 
separately into two models, once with only PCPs, and once with PSYCHs. The variables which were 
found to be significant at an alpha of 0.1 were then entered together into a final model for each specialty. 
The significant predictors for each specialty model, at an alpha of 0.05, were then identified and entered 
into an overall model which included the entire sample. This model was used to test the significance of 
the interactions of these predictors with physician specialty.  
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ABSTRACT 
Objective: The objective of this study is to determine how patient and physician level factors 
influence decisions to prescribe atypical antipsychotics to children (under 18years) diagnosed 
with psychosis. 
Methods: This study is a cross-sectional survey of general practitioners and psychiatrists. A 
web-based patient simulation survey using fractional factorial design was administered with 
the help of a commercial vendor. Respondents were presented with simulated patient profiles 
that contained various levels of factors considered to be essential to decision making. 
Physician treatment decisions were measured along with demographics and beliefs about 
products. Marginal modelling using General Estimating Equations were used for analysis. 
Results: Patient age, disease severity, physician specialty and belief about evidence supporting 
use of the drug were found to significantly influence physician prescribing decisions. 
Conclusions: This study shows that patient age and other factors are important when 
physicians from different specialties are making decisions about the use of antipsychotics.   
Keywords: Atypical antipsychotics, children, psychiatrists, pediatricians, psychosis 
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DETERMINING PHYSICIAN AND PATIENT CHARACTERISTICS THAT PREDICT THE 
USE OF ATYPICAL ANTIPSYCHOTICS IN CHILDREN WITH MENTAL HEALTH 
DISORDERS 
Atypical antipsychotics (AP) are approved for use in some children below 18 years of age 
for diseases such as schizophrenia and bipolar disorder. The use of these drugs has increased 
exponentially over the past few years (Pathak, West, Martin, Helm & Henderson, 2010). Even 
though there is limited evidence of the effects of these drugs in children, they are being 
prescribed for children for several different conditions.  Existing studies point toward a range of 
potential serious adverse events such as weight gain, diabetes, hypertension, metabolic and 
endocrine abnormalities, hyperprolactinemia, dyslipidemia in the short term and several other 
unknown long-term effects (Vitiello et al., 2009; McIntyre & Jerrell, 2008; Fedorowicz & 
Fombonne, 2005; Kumra et al., 2008). With increasing safety concerns and budgetary 
constraints, payers such as Medicaid have sought to better understand the use of these drugs in 
children (Surles, 2005; Strawbridge, 2011).
In 2011, a Government Accountability Office (GAO) study examined the rates of use of 
psychotropic medication among foster children in several state Medicaid programs and 
recommended to the Department of Health and Human Services that they should provide 
guidance to states on best practices for overseeing psychiatric prescriptions (Kutz, 2011). In 
response to this, the Department of Health and Human Services (DHHS) sent a letter to the state 
directors making them aware of the growing problem of safe, appropriate and effective use of 
 
 
32 
 
psychiatric prescriptions among foster children. They proposed an expansion of activities and 
collaboration between the Administration for Children and Families (ACF), the Center for 
Medicare and Medicaid Services (CMS) and the Substance Abuse and Mental Health Services 
Administration (SAMHSA) (DHHS, personal communication, November 23, 2011). 
The increasing recognition from the FDA and the DHHS demonstrates the importance of 
addressing the issue of use of APs in children. This study aims to help understand the process of 
prescription decisions better so all of the players in the health care system can plan for better 
ways to assure more efficient and safer use of APs in children and adolescents. The objective of 
this study is to identify the patient and physician level factors that most influence physicians’ 
decisions to prescribe APs in children and adolescents less than 18 years of age
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LITERATURE REVIEW 
Use of atypical antipsychotics 
Cooper et al. (2006) found that the use of APs for approved indications grew 2.49 times 
between the periods 1995-1998 and 1999-2002, while the use for the unapproved indications 
grew 3.52 times. Interestingly, the article also concluded that 30% of all antipsychotic 
prescriptions were attributable to non-psychiatrists. Evidence available from an expert panel 
convened by the European Neuro-psychopharmacology, to study efficacy and safety data, states 
that children and adolescents are more vulnerable to side-effects from APs than are adults 
(Vitiello et al., 2009). Research suggests that some risk factors may be associated with children’s 
susceptibility to the side-effects of these drugs. McIntyre and Jerrell (2008), studying the pattern 
of adverse events associated with the use of APs in children and adolescents in the South 
Carolina Medicaid database, found that children treated with these drugs have the risk of 
acquiring diseases such as obesity, type II diabetes, dyslipidemia and orthostatic hypotension 
among others.
Olfson, Blanco, Liu, Moreno & Laje (2006) conducted research into various patient 
characteristics related to AP use. They found that more males receive APs than do females; and 
that children insured by Medicaid are prescribed more APs than privately insured children. 
While the reasons for this differential use have not been established by research, many of these 
patterns have been documented in multiple studies (Olfson et al., 2006; Hamann, Langer, Leucht, 
Busch & Kissling, 2004; Pathak et al., 2010).  
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The letter sent to the Medicaid state directors from the Department of Health and Human 
Services mentions that factors such as age, gender, behavioral concerns and placement type (for 
foster children) can affect likelihood of being prescribed psychotropic medications (DHHS, 
personal communication, November 23, 2011; Strawbridge, 2011). 
Prescription decisions 
The study of prescription decision making has been well researched over the years. Some 
researchers have compared the act of prescribing to an art that goes beyond mere 
pharmacological factors. It has been called a complex skill that requires the physician to 
carefully evaluate the patient’s physical, psychological, social and behavioral illnesses and weigh 
the benefits and risks of each treatment alternative and comparing it to the option of not treating 
the indication (Howie, 1976). 
There is also a lot of evidence to suggest that prescription decision making is not 
dependent only upon clinical factors. In his study on antibiotic use in cases of sore throat, Howie 
(1976) demonstrated that social and psychological information about the patient can substantially 
influence prescription decisions. Bradley (1992a), in an attempt to study uncomfortable 
prescription decisions, found that any prescription decision involving concern about toxicity, 
failure to live up to expectations, concern about appropriateness and uncertainty caused 
discomfort among physicians. It seems many of these conditions apply directly to APs. 
In an experimental study conducted in Peru, researchers concluded that knowledge about 
disease seems to make very little difference as to what the physician prescribes. They describe 
the decision making process as social and not logical. They identified a few important social 
factors such as the physician’s role as a socially defined good practitioner, previous experiences 
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with diarrhea cases and sometimes even deficiencies in knowledge (Paredes, De La Pena, Flores-
Guerra, Diaz & Trostle, 1996). 
In another study, researchers found that the physicians’ perceptions of patients’ 
expectations influenced prescribing behavior the most. Other factors such as the patient’s age, 
ethnic group and symptoms also influence prescribing behavior. They showed that the 
physician’s perception of the patient’s expectations in turn seemed to depend on the patient’s 
symptoms, complaints, age and even on the physician’s own qualifications. The study essentially 
pointed out the importance of patients’ social variables in making prescription decisions (Britten 
& Ukoumunne, 1997). Bradley (1992b) characterized a list of factors influencing prescribing 
decisions into three general categories: patient factors, physician factors and physician concern 
about drugs or product factors. He found that several psychotropic drugs and psychiatric 
conditions were associated with discomfort when prescribing. The current study attempts to 
identify the specific patient and physician factors influencing prescribing of APs in children with 
psychosis.
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RESEARCH OBJECTIVES 
This study has two specific objectives: First, to determine how patient level factors, such 
as age, race, sex or attitude about consent from parent/guardian influence physicians’ decisions 
about prescribing atypical antipsychotics in children under 18 years of age. Second, to determine 
how physician characteristics, such as specialization, mental health patient volume or beliefs 
about drugs influence physician’s decision to prescribe APs in children under 18 years of age.
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METHODS 
Study design and data collection 
The study is a cross-sectional survey of Psychiatrists (PSYCHs) and Primary Care 
Practitioners (PCPs). General psychiatrists and child psychiatrists were classified as PSYCHs, 
and family medicine, internal medicine, general practice and pediatricians were classified as 
PCPs.  A stratified quota sample of physicians was drawn for the purpose of this study. The 
sample was be obtained through a national physician panel maintained by Reckner Healthcare, a 
commercial vendor. Physicians were required to go through a small set of screening questions to 
make sure they met the inclusion criteria for the study. To be eligible for the study, physicians 
had to be engaged in full-time active practice for at least 2 years post-residency and spend a 
majority of their time in the outpatient care setting (50% for PCPs and 25% for PSYCHs). 
Physicians were excluded from the survey if their practice did not include any mental health 
patients under 18 years of age, any patients with a diagnosis of psychosis or any patients taking 
APs.
Survey design 
A patient simulation was performed to best replicate actual treatment decisions. Each 
physician was presented a set of patient cases/profiles with information about demographics, 
symptoms, clinical parameters and other relevant information. The respondent then chose a 
treatment plan for each patient from a list of exhaustive options. The information presented in 
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each profile was carefully constructed, from current literature, to include variables that were 
expected to be relevant to decision making. Several one-on-one interviews were conducted with 
psychiatrists, pediatricians and mental health pharmacists to finalize the patient attributes. The 
list of variables that were present on the profiles and their various levels are presented in Table 1. 
An orthogonal design was used to find the combinations of various levels of these patient 
attributes that would support statistical analysis of the effect of each attribute independently. A 
total of 30 profiles were created out of the combination of variables listed. (See Appendix A for a 
sample patient profile). 
Each respondent viewed one of three randomized blocks containing only 10 out of the 30 
profiles. Each block of profiles was balanced with respect to age of patients and disease severity. 
The survey also contained the Evidence Based Practice Attitude Scale (Aarons, 2004),  measures 
of physician background, practice characteristics and beliefs about evidence supporting use of 
atypical antipsychotics in children with psychosis.  
Physician’s belief about evidence concerning use of atypical antipsychotics in children 
with psychosis was measured by asking respondents their beliefs about the level of evidence that 
existed for use of the 11 atypical antipsychotics for the three age categories presented in the 
patient profiles. The level of evidence categories were ‘labeled indication’, ‘medically accepted 
use but not a labeled indication’, or ‘no evidence supporting use’.  Respondents could also 
indicate they ‘don’t know’. The maximum level of evidence found for any atypical antipsychotic 
was used for the corresponding age group. Full approval for the study was obtained from the 
University of Mississippi Institutional Review Board prior to data collection.
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DATA ANALYSIS 
The data collected from the survey was analyzed using IBM SPSS (Chicago, Illinois). 
Physician treatment choice was modelled using marginal modelling using Generalized 
Estimating Equations (GEE), with a logit link function, to account for the lack of independence 
in the dataset. Model building was done in multiple steps (Hosmer, & Lemeshow, 2004). 
Potential physician and patient factors were introduced in separate models, once for the PCPs 
and once for PSYCHs. The factors that were found to be significant (alpha ≤ 0.1) were then 
introduced in the respective PCP and PSYCH overall models. A final model included both 
specialties while testing for interaction of physician specialty with significant predictors in the 
PCP and the PSYCH models.
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RESULTS 
In all, the contracted vendor provided the researchers with 215 completed surveys. Of all 
respondents who attempted the survey about 50% met the qualifying criteria set by the 
researchers. The average respondent took about 19 minutes to complete the survey. To ensure 
data quality, the researchers, after thorough analysis of response patterns, deleted  from the final 
dataset respondents that prescribed more than three non-AP drugs in two or more patient 
profiles.  A total of 193 respondents, or 1,930 unique physician-patient combinations, were used 
in the analyses.
Physician characteristics 
Summaries of respondent demographics and beliefs are provided in Tables 2 and 3. All 
physicians were classified as either Primary care practitioners (PCPs) or Psychiatrists (PSYCHs) 
based on their specialization. The final dataset for analysis contained 129 respondents classified 
as PCPs and 64 classified as PSYCHs.  
The mean age of PCPs in the final dataset was 50.2 years and the mean age of PSYCHs 
was 54.1 years. The respondents were composed of 17.2% females; 63% Caucasians and 27% 
Asian Americans. Distribution within race and gender was similar across the specialties. Given 
the distribution obtained, the race variable was recoded as Caucasian, Asian American or other, 
in order to reduce correlation between independent variables in the final model.  
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PSYCHs were found to be significantly older, have spent more years in active practice, 
have higher patient volume in a typical week, and have a higher percentage of patients who are 
foster children. In line with expectations, PCPs were found to spend a significantly greater 
proportion of their time in outpatient care (92% versus 80% for PSYCHs). On the evidence 
based practice attitude scale, which measures the extent of evidence driven practice behavior, it 
was found that PSYCHs had significantly higher scores on the overall score and the openness 
subscale (subscale 3) (see Table 3).  
Prescribing patterns 
Across all physicians and patient profiles, 1,930 (71.2%) patients were treated with APs 
(Table 4). Significant difference in prescribing patterns between PCPs and PCYCHs were 
observed for prescribing of APs and referrals to another physician. PCPs were more likely to 
refer the patient to another physician (50% vs 16% for PSYCHs) and less likely to prescribe APs 
themselves (63.6% for PCPs vs 86.6% for PSYCHs). Further, PCPs were also significantly less 
likely to prescribe psychosocial therapy to their patients (44% vs 55% for PSYCHs). 
Factors influencing prescribing behavior 
GEE models were used to identify factors that influences prescribing behaviors.  
Complete results from these models are shown in Table 5. 
It was found that belief about evidence supporting use of APs, patient disease severity 
and patient age significantly predicted prescription behavior among both PCPs and PSYCHs. 
PCPs and PSYCHs differed significantly in their prescribing behavior with changes in patient 
WBC count, disease severity, proportion of patient population diagnosed with psychosis and the 
proportion of patients using APs.
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DISCUSSION 
The results of this study point out that there are considerable differences between the 
practices of PCPs and PSYCHs. PSYCHs were more likely than PCPs to prescribe APs for 
young patients. This finding is along the same lines as Cooper et al. (2006) who found that 
increase in frequency of use of APs by ‘mental health providers’ was more than twice the 
increase seen in ‘non-mental health providers’. Since a large percentage of children with mental 
health problems are treated by PCPs, it is important to understand these differences and how they 
might affect the quality of care received by children.  These differences might arise due to a large 
number of reasons, some of which were identified in this study. 
Patient characteristics 
The important patient characteristics that best predicted prescribing of APs were age and 
disease severity. It appeared that patients were more likely to be prescribed atypical 
antipsychotics when their disease was severe or moderate, in comparison to mild severity. This is 
in line with the expectation that increasing severity requires immediate and intensive therapy 
(Gleason et al, 2007). Among PSYCHs, the odds ratio for moderate patients is approximately 
2.54 (95% CI = 1.626-3.961), whereas that for the severe patients is 3.51 (95%CI = 1.870-
6.530). Although PCPs were more likely to prescribe APs as severity went up, they did not 
differentiate between moderate and severe patients the way PSYCHs did.  The odds ratio for 
PCPs for mild to moderate patients was 1.35 (95% CI = 1.023-1.017) and for mild to severe was 
1.29 (95% CI = 0.917-1.814). The difference in responses to severity level was significant as 
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shown by the interaction of specialty with disease severity. This might be explained by the fact 
that PCPs may not be as comfortable treating patients with increased severity and preferred to 
refer such patients to specialists. This interpretation is supported by the increased rate of referrals 
as shown in Table 4 (50% for PCPs vs 16% for PSYCHs). Documented expert interviews 
corroborate the hypothesis that most PCPs are likely to refer patients as soon as psychotic 
symptoms are identified (Sussman, 2008).  
As expected, changes in prescription patterns were associated with changes in patient 
age. Physicians prescribed fewer APs to younger children, with an odds ratio of 0.32 (95% CI = 
0.212 - 0.476) for 4 year olds and 0.69 (95% CI = 0.534 – 0.880) for 10 year olds when 
compared to 15 year olds.  Pathak et al. (2010) also found that use of APs increases with 
increases in patient age. Prescription patterns among PCPs and PSYCHs did not significantly 
with respect to changes in patient age.  
Patients with abnormally low WBC counts were found to be significantly less likely (p < 
0.05) to be prescribed APs. Normal values of patient WBC count did not predict prescription 
behavior in the model for the PSYCHs (OR = 0.65; 95% CI = [0.412-1.029]), but was significant 
in the model for PCPs (OR = 1.37; 95% CI = [1.129-1.668]). The significance of WBC count in 
treating children with mental health disorders is not unheard of in published literature. WBC 
values are suggested for constant monitoring (every 2 or 4 weeks), especially if the patient is 
using clozapine, because it has a blackbox warning listed for agranulocytosis (Texas Department 
of Family and Protective Services, 2010; Gasper & Tsai, 2006). While this effect does not seem 
to exist across all atypical antipsychotics, it still seems to drive prescription behavior among 
PCPs.  
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Not all APs have labeled indications for use in young children with psychosis; therefore, 
the level of parent or guardian concern when providing consent for their use was hypothesized to 
be a factor influencing decisions about using APs in the study (Strawbridge, 2011).  Parent or 
guardian’s concern about use of APs and patient’s foster status (foster child or not) were not 
found to be significant predictors. These factors failed to meet the alpha of 10%, in the initial 
models for each physician type and thus were not included in the final models. Patient sex, race, 
BMI, puberty status, alcohol use and blood glucose levels also did not meet the criteria for 
inclusion in the models for each physician type. It was surprising that none of these factors were 
significant predictors, because literature presents some contrasting evidence. For example, 
weight gain is a significant side effect with most APs and monitoring patient’s BMI is 
recommended by several guidelines (Texas Department of Family and Protective Services, 2010; 
Gasper & Tsai, 2006; Culpepper, 2007; Teicher & Glod, 1990; Varley & McClellan, 2009). 
Similarly, monitoring puberty or sexual function is also recommended by guidelines for 
prescription of APs (Texas Department of Family and Protective Services, 2010). 
The studies which highlight the disproportionately high use of APs in foster children, 
suggest that this might be because of greater exposure to trauma, frequent changes in foster 
placement and varying state oversight policies (Kutz, 2011; Strawbridge, 2011; Zito et al., 2008). 
The finding that physicians are no more likely to prescribe these drugs to foster children provides 
evidence that increased use of atypical antipsychotics in foster children is driven by clinical 
factors and not on foster status of the child. A similarly positive finding is the non-significance 
of the factor ‘parental concern’. This finding reinforces the belief that physician decisions are 
driven more by objective clinical criteria. 
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Physician characteristics 
As previously discussed in the results section, the most important physician characteristic 
was specialty. Cooper et al. (2006) found similar results in their study on trends in prescription of 
APs using data from the National Ambulatory Medical Care Survey and the National Hospital 
Ambulatory Medical Care Survey.  
Only one other physician factor, belief about evidence supporting use of APs, was found 
to be a significant predictor (p < 0.001) among both PCPs and PSYCHs. This variable was 
measured separately for each specific patient age category for the psychosis diagnosis. 
Physicians prescribed significantly more atypical antipsychotics when they believed there was 
evidence to support use, either labeled or medically accepted. 
The proportion of patient population diagnosed with psychosis (OR = 0.96; 95% CI = 
[0.933-0.987]; p < 0.01) and the past use of APs (OR = 1.04; 95% CI = [1.014-1.062]; p < 0.01) 
were also found to significantly predict PSYCH prescribing behavior, but not PCP behavior. 
However, as shown by the odds ratios and the confidence intervals, these ratios are barely 
significant and the magnitude of the ratios indicates they do not have a meaningful impact on 
prescribing decisions.  
Limitations 
This study provides valuable contributions to our understanding of decisions related to 
prescribing APs for children.  As with any study, however, there are a few limitations that need 
to be considered. A national panel of physicians was used for this study. A summary of the study 
results was offered as the only incentive for participation. There exists a potential risk for non-
response bias since the only incentive was information about the results.   The sample obtained 
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was skewed in terms on distribution for race (majority Caucasians and Asian Americans) amd 
gender (17% female) which could further limit generalizability of the findings. The low sample 
size also resulted in an underpowered study, especially for PSYCHs.  This could have resulted in 
missing other effects which might have been significant predictors of prescribing decisions. This 
study used the diagnosis of psychosis in its patient profiles. Generalizations to other mental 
health conditions in children must be made with caution.  
Further, even though patient simulation was used to capture treatment decisions, it is not 
possible to capture to the actual decisions made during patient visits other than through chart 
reviews. The patient profiles were revised several times to provide the information a physician 
would have and need during a regular office visit for this type of patient.  However, respondents 
were not able to acquire additional information they may have felt was needed.  Since the patient 
simulation process does closely replicate the actual decision making process in practice,  this 
bias, if present, was considered to be minimal.
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CONCLUSIONS & FUTURE STUDY 
Clinical Relevance 
This study shows that physicians’ prescribing of APs in children with psychosis is 
heavily influenced by factors such as patient age, disease severity, physician specialty and belief 
about evidence supporting use of the drug.  More importantly, this study demonstrated 
differences in prescribing behaviors for PCPs and PSYCHs when treating the same patients.  
This study can provide guidance for strategies for assuring clinically appropriate and safe 
use of antipsychotics in children. For both types of physicians, patient age and disease severity 
were significant factors in treatment decisions. This indicates that most physicians are 
appropriately considering clinical factors. Overall, physicians were significantly influenced by 
their beliefs about evidence based prescribing. This is important in that it indicates that education 
about clinical appropriateness will influence prescribing of APs. 
Future study 
While this study contributes to the pediatric psychology literature, there is a lot of scope 
for further research. The present study only deals with children of ages 4, 10 and 15 years with 
psychosis, and cannot be generalized to all mental health conditions in children under 18 years. 
The most common conditions observed in children today are ADHD, Autism, Oppositional 
Defiant Disorder, etc. These diseases can be much more challenging to diagnose and are also 
liable to overprescribing. The factors influencing prescriptions in these disease states also need to 
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be better understood, since they account for a large percentage of the use of APs in children 
today.  
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Table 1: List of Patient Attributes 
VARIABLE 
NAME VARIABLE DESCRIPTION 
VARIABLE LEVELS 
0 1 2 
Pt_severity Disease severity Mild Moderate  Severe 
Pt_Adherence Risk for non-adherence Absent Present - 
Pt_WBC WBC count Low Normal - 
Pt_ANC ANC count Low Normal - 
Pt_Alc Alcohol / Substance abuse No Yes - 
Pt_BMI BMI Underweight Normal Overweight 
Pt_Sex Sex Male Female - 
Pt_Race Race Caucasian Black - 
Pt_Age Age <5 6 – 12 13 – 17 
Pt_Puberty Puberty No Yes - 
Pt_Caregiver Type of caregiver Parent Guardian - 
Pt_Diabetes Type 2 Diabetes mellitus No Yes - 
Pt_Consent Concern about consent None Medium High 
Table 2: Respondent demographics 
Variable Physician specialty 
PCP (N = 129) PSYCH (N = 64) 
Age**                                                          50.28 (7.957) 54.17 (8.759) 
Females#                                                            22 (17.1) 11 (17.2) 
Race#   
             Caucasians 80 (62.0) 42 (65.6) 
             Asian Americans 36 (27.9) 16 (30.8) 
             African Americans 2 (1.6) 0 (0) 
             Native Hawaiians 1 (0.8) 0 (0) 
             Hispanics 3 (2.3) 0 (0) 
             Others 7 (5.4) 6 (9.4) 
Years in practice* 17.99 (6.945) 20.17 (7.030) 
Patient volume per week*** 174.55 (122.654) 108.30 (74.485) 
% of patients in foster care** 9.08 (11.770) 15.95 (17.100) 
% of patients using atypical antipsychotics 27.39 (26.531) 35.05 (24.393) 
Proportion of time spent in   
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           Inpatient care** 6.37 (10.694) 14.80 (18.871) 
           Outpatient care*** 92.00 (12.094) 80.03 (21.743) 
           Administration* 1.16 (2.561) 2.69 (4.757) 
          Teaching/Research .47 (1.719) 2.48 (6.512) 
Proportion of patients diagnosed with   
          Psychosis** 10.83 (12.624) 18.33 (16.588) 
          Bipolar disorder* 17.73 (16.155) 23.16 (13.046) 
          Conduct disorder** 29.53 (27.028) 20.52 (14.573) 
          Autism 11.95 (13.358) 13.63 (11.928) 
Proportion of age groups   
          5 and under 4.02 (5.750) 4.59 (7.849) 
          6 to 12 years** 8.46 (8.203) 13.56 (14.115) 
          13 to 17 years 15.79 (11.813) 18.03 (10.936) 
          18 and over* 71.74 (21.481) 63.81 (27.675) 
Profiles who were prescribed atypicals 820 (63.6) 554 (86.6) 
All values are Mean(Standard Deviation); except # (N and percent);  
*** - p < 0.001; ** - 0.001 < p < 0.01; *- 0.01 < p < 0.05; 
 
 
Table 3: Physician beliefs about evidence for use of atypical antipsychotics 
Variable Physician specialty 
 PCP (N = 129) PSYCH (N = 64) 
Physician’s belief about evidence for use of AP in children 5 years and under 
          Medically accepted use 17 (13.2) 14 (21.9) 
          No evidence 45 (34.9) 27 (42.2) 
          Don’t know 33 (17.1) 13 (6.7) 
Physician’s belief about evidence for use of AP in children between 6 and 12 years* 
          Labelled indication 24 (18.6) 6 (9.4) 
          Medically accepted use 8 (6.2) 6 (9.4) 
          No evidence 48 (37.2) 17 (26.6) 
          Don’t know 49 (38) 35 (54.7) 
Physician’s belief about evidence for use of AP in children between 13 and 17years 
          Labelled indication 15 (11.6) 3 (4.7) 
          Medically accepted use 2 (1.6) 2 (3.1) 
          No evidence 36 (27.9) 13 (20.3) 
          Don’t know 76 (58.9) 46 (71.9) 
Evidence Based Practice Attitude Scale (EBPAS)# 
          Requirement 1.83 (1.068) 1.93 (1.071) 
          Appeal 2.47 (.784) 2.68 (.621) 
          Openness** 2.07 (.864) 2.46 (.816) 
          Divergence 2.457 (.875) 2.34 (.890) 
          Total 2.21 (0.480) 2.35 (0.483) 
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All values are N and percent; except #: Mean(Standard Deviation);  
EBPAS and subscales are scored on a scale of 0 to 4. 
*** - p < 0.001; ** - 0.001 < p < 0.01; *- 0.01 < p < 0.05; 
 
 
 
Table 4: Prescribing patterns across all profiles displayed 
Treatment Physician specialty 
PCP PSYCH 
Atypical Antipsychotics   
                       5 years an under*** 45.99 74.66 
                       6 to 12 years*** 67.22 91.19 
                       13 to 17 years*** 78.29 94.79 
                       All age groups*** 63.57 86.56 
Other pharmaceutical treatment   
                       5 years and under 30.42 31.67 
                       6 to 12 years  45.51 40.53 
                       13 to 17 years 45.99 41.67 
                       All age groups 40.7 37.81 
Psychosocial treatment   
                       5 years and under*** 38.92 60.18 
                       6 to 12 years* 46.35 54.19 
                       13 to 17 years 48.32 52.08 
                       All age groups*** 44.5 55.63 
Referral to another physician   
                       5 years and under*** 59.91 23.53 
                       6 to 12 years*** 47.81 15.42 
                       13 to 17 years*** 42.64 10.42 
                       All age groups*** 50.23 16.72 
All numbers are expressed as a percentage of the total population in that age group 
*** - p < 0.001; ** - 0.001 < p < 0.01; *- 0.01 < p < 0.05; 
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Table 5: Comparison of factors influencing physician prescription of atypical antipsychotics in 
three models 
 
Characteristics 
Physician specialty OR (95% CI) 
PCP PSYCH 
Psychiatrists 0.328 (0.012 – 9.259) 
Physician’s belief about evidence supporting use 
 Labelled indication 5.70 (3.034-10.707)*** 
 Medically accepted  use 3.70 (1.949-7.023)*** 
Physician Race 
 Asian American  1.257 (0.553 -2.859) 
 Caucasians 0.819 (0.376- 1.785) 
Proportion of patients diagnosed with 
psychosis 
1.01 (0.989 – 1.024) 0.96 (0.933-0.987)** 
Proportion of patients using atypicals 1.01 (0.995 – 1.017) 1.04 (1.014-1.062)** 
Years spent in active practice 1.031 (0.990-1.074) 
Patient 
severity
  
 Severe 1.29 (0.917-1.814) 3.51 (1.870-6.530)*** 
 Moderate 1.35 (1.023-1.783)* 2.54 (1.626-3.961)*** 
Patient age  
  4 years 0.32 (0.212 – 0.476)*** 
 10 years 0.69 (0.534 – 0.880)** 
Patient WBC Count (Normal range) 1.37 (1.129-1.668)** 0.65 (0.412-1.029) 
Patient ANC count (Normal range) 0.924 (0.755 – 1.131) 
*** - p < 0.001; ** - 0.001 < p < 0.01; *- 0.01 < p < 0.05;  
Separate odds ratios are provided for PCPs and PSYCHs wherever the interaction between 
them is significant at the 0.05 level. 
Reference category - Psychiatrists: PCPs; Evidence supporting use: No evidence available; 
Physician Race: Other; Patient severity: Mild; Patient age: 15 years; Patient WBC count: Low 
WBC count; Patient ANC count: Low ANC count; Patient adherence: Non-adherent. 
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SUMMARY & CONCLUSIONS 
This study shows that physician prescribing of APs in children with mental health disorders can be 
predicted based on factors such as patient age, disease severity, physician specialty and beliefs about 
evidence supporting use of the drug.  It provides valuable insight into the prescription decision making 
process. It helps understand the characteristics that are important to physicians when they make a 
prescription decision. More importantly, this study showcases the differences in prescribing behaviors of 
PCPs and PSYCHs and goes further to explain what might drive these differences. 
This information is valuable for policy makers trying to assure safe and effective use of APs in children. 
It provides an understanding for State Medicaid directors and other payers who might be trying to control 
rising costs, while not jeopardizing rational care. Because it explains the differences between PCP and 
PSYCH prescribing patterns, it might be possible to put in place step edits or prior authorizations or other 
such mechanisms tailored to the prescribing physician. 
The effect of the belief about evidence, can help formulate a strategy for policy makers to curtail 
inappropriate use. If physicians can be educated about drug labelling status and acceptable medical use 
for each AP for specific age categories and diagnoses, it will encourage use only in indications approved 
by the FDA. Further, because PCPs were found to be prescribing fewer atypicals than PSCYHs and they 
often indicated referral of patients to specialists, these physicians are probably less knowledgeable about 
or comfortable with prescribing APs, especially for children.  It may be important to have patients 
managed by these physicians routinely evaluated by a qualified child psychiatrist or other appropriate 
person in order to assure appropriate use. Some states, such as Florida, require all physicians to obtain a 
standardized written consent from the parent or guardian before a psychotropic drug is administered 
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(Kutz, 2011). While this might still contribute toward standardized data collection, this study shows that 
any concern that a parent or guardian might express during this interaction does not significantly 
influence physician treatment decisions.  
This study also helps pharmaceutical marketing managers who are trying to introduce a product in this 
market. The study establishes the value a labelled indication holds in this market. Currently, only Abilify, 
Zyprexa, Seroquel, Invega and Risperidal are approved for treatment of schizophrenia in the age group 13 
to 17 years. Abilify and Risperidal are also approved for treatment of irritability associated with autistic 
disorder in children of ages 6 to 17. It is apparent that approved indications in this market are rare. 
Several other indications, which are growing in the past decade do not have any approved treatments. 
This study shows that pharmaceutical companies who are aiming to capture the child and adolescent 
market in APs need to get the indication approved or establish their product as an acceptable medical use. 
Although physicians may generalize the level of evidence to the class of products, clinical edits at time of 
prescription adjudication can easily limit use to appropriate levels of evidence.   
Future Research: 
While this study contributes to the pediatric psychology literature, there is a lot of scope for further 
research. The present study only deals with children with psychosis and cannot be generalized to all 
mental health conditions in children.  Diseases such as ADHD, Autism, and Oppositional Defiant 
Disorder are being commonly diagnosed in children (Pathak et al., 2010). These disease can be much 
more challenging to diagnose in a single clinic visit and also highly liable to overprescribing. The factors 
influencing prescriptions in these disease states also need to understood, since they account for a lot of 
use of antipsychotics today.  Further research is also needed to understand how physician decision making 
is influenced by changes in regulatory framework in order to understand which form of regulation is best 
suited in order to curb over utilization of APs. 
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(102) Elizabeth: 
Doctor, please assume that Elizabeth is a patient you have newly diagnosed with mild psychosis. Her history and your current 
evaluation notes are summarized below.
Demographics Lab values Symptoms 
Age: 15 
  
Gender: Female 
Height: 63.7 inches 
Weight: 119.5 pounds 
BMI: 20.7     (Normal) 
 
Pubescent 
         
Caucasian 
 
WBC: 7300 (Normal) 
    
ANC: 1300 (Low) 
     
Fasting glucose: 85mg/dL 
Patient has displayed symptoms of mild 
psychosis: 
• Occassional uncontrollable 
agitation 
• Minimally intrusive auditory 
hallucinations 
• Mild lack of age-appropriate 
grooming 
 
The patient’s diagnosis is consistent with family history. You have informed the parent about the use of atypical antipsychotics. 
The patient can afford her drugs. 
During the visit you determine that: 
• The parent is willing to sign an informed consent and hasn’t expressed any concerns about the use of antipsychotics. 
• The patient has no history of alcohol abuse. 
• The parent mentions that the patient takes her medications on time. 
 
Treatment options:  (Please check all that apply) 
 
Atypical Antipsychotics 
 
 Aripiprazole (Abilify®) 
 Asenapine (Saphiris®) 
 Clozapine (Clozaril®, generic) 
 Iloperidone (Fanapt®) 
 Lurasidone (Latuda®) 
 Olanzapine (Zyprexa®, Zyprexa Relprevv®, generic) 
 Olanzapine & Fluoxetine (Symbyax®, generic) 
 Paliperidone (Invega®, Invega Sustena®) 
 Quetiapine (Seroquel®, Seroquel XR®, generic) 
 Risperidone (Risperidal, Risperidal Consta®, generic) 
 Ziprasidone (Geodon®, generic) 
 
Conventional Antipsychotics 
      Perphenazine (Trilafon®, generic) 
      Chlorpromazine (generic) 
      Others 
 
Anti-convulsants 
       Lithium (Lithobid®, generic) 
       Alpha agonists 
       Other 
 
 Anti-depressants 
 Anxiolytics 
 Mood stabilizers 
 Stimulants 
 Other (Please specify ______) 
 Psychosocial Intervention 
 Refer to another physician with experience in dealing 
with pediatric mental health 
 Refer to non-medical practitioner 
 Other non-pharmaceutical treatment 
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COVER LETTER:  
J. Reckner Associates is helping the University of Mississippi conduct a research study regarding the use 
of antipsychotics in children with mental health disorders as part of a graduate student thesis project. 
We request your participation in this study.
A few points to note: 
• The survey is expected to take approximately 40 – 45 minutes to complete. 
• As always your responses will be held confidential. 
• The identities of the respondents will not be made available in any form to the research team at 
the University of Mississippi. 
• This study has been reviewed and approved by the University of Mississippi Institutional Review 
Board (IRB). The IRB has determined that this study fulfills the human research subjects’ 
protection obligations required by state and federal law and University policies. If you have any 
questions, concerns or reports regarding your rights as a participant of research, please contact 
the IRB at (662)915-7482. 
• Your response is of great importance to us. As an academic project, we are unable to offer you 
an honorarium. However, to show our appreciation for your time, respondents will be sent a 
summary report of the results from the study by Reckner Associates after the analysis has been 
completed.  
The survey will available only for a limited time. Please complete the survey as soon as possible.  
Please click on the following link to enter the survey.  
[ENTER LINK] 
Thank you for your cooperation. 
Best regards. 
 
INTRODUCTION MESSAGE: 
Welcome to our study, Doctor. The aim of this study is to understand the use of antipsychotics in 
children suffering from mental health illnesses. 
Please answer the next few questions to determine if you meet the criteria for inclusion in our study. 
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SCREENER: 
1. Which area of specialization best describes your practice? 
(1) Family practice        (PCP) 
(2) Internal medicine                 (PCP) 
(3) Pediatrician       (PCP) 
(4) General practice      (PCP) 
(5) General Psychiatrist      (PSYCH) 
(6) Child and adolescent psychiatrist   (PSYCH) 
(7) Other        (DISQUALIFY) 
  
2. Are you engaged in full-time active practice? 
(1) Yes     
(2) No    (DISQUALIFY) 
 
3. For how many years have you been in practice, post-residency? ______ (DISQUALIFY IF LESS 
THAN 2YEARS) 
 
4. Please indicate what percentage of time you spend in each of the following areas:  
(Sum must equal 100%) 
IF SUM IS GREATER THAN 100, SHOW WARNING MESSAGE, “Sum must equal 100%.” 
 
Type of practice Percentage of time spent 
Inpatient care  
Outpatient care FOR PCPs - DISQUALIFY IF LESS THAN 50% 
FOR PSYCHs - DISQUALIFY IF LESS THAN 25% 
Administration  
Research / Teaching  
SUM (Must total 100%) (DISPLAY SUM – MUST TOTAL 100%) 
 
For the purposes of this study ‘mental health disorders’ will include, but not be limited to, indications 
such as schizophrenia, bipolar disorder, Attention Deficit Disorder (ADD)/ Attention Deficit Hyperactivity 
Disorder (ADHD), autism, tourette’s syndrome, dementia, delirium, conduct disorders, behavioral 
disorders, depression, borderline personality disorder, anorexia, psychosis, pervasive developmental 
disorder, etc. 
DISPLAY QUESTIONS 5 TO 7 ON THE SAME SCREEN  
5. Approximately, how many patients do you see in outpatient care in a typical week? _______ 
DISPLAY Q6 TO PCPs ONLY. 
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6. Of the patients you see in a typical week, how many patients are you treating for any mental 
health disorders? 
____ 
7. DISPLAY Q7a to PCPs ONLY. DISPLAY Q7b to PSYCHs ONLY.  
7a.What percentages of the patients that you treat for mental health disorders would you 
estimate are in each of the following age groups? Sum of all percentages must equal 100%. 
5 years and under            ____% 
6 to 12 years      ____% 
13 to 17 years   ____% 
18 years and older             ____% (DISQUALIFY IF 100%) 
Total (must sum to 100%)   _____% (DISPLAY SUM)  
 
IF SUM IS GREATER THAN 100, SHOW WARNING MESSAGE, “Sum must equal 100%.” 
7b.What percentages of the patients you see in outpatient care would you estimate are in each 
of the following age groups? Sum of all percentages must equal 100%. 
5 years and under            ____% 
6 to 12 years      ____% 
13 to 17 years   ____% 
18 years and older             ____% (DISQUALIFY IF 100%) 
Total (must sum to 100%)   _____% (DISPLAY SUM)  
 
IF SUM IS GREATER THAN 100, SHOW WARNING MESSAGE, “Sum must equal 100%.” 
8. What percentage of your patients less than 18 years of age that you are treating for mental 
health illnesses would you estimate have each of the following diagnoses? 
(1) Psychosis -   __% (DISQUALIFY IF 0%) 
(2) Bipolar disorder -  __% 
(3) Conduct disorder -   __%  
(4) Autism -  __% 
Total does not have to sum to 100%. 
9. What percentage of your patients, less than 18 years of age, is currently in foster care? ___% 
10. What percentage of your patients less than 18 years of age that you are treating for mental 
health disorders are currently taking atypical antipsychotics? ___%   (DISQUALIFY IF 0%) 
FOR RESPONDENTS WHO DO NOT QUALIFY, SHOW THE MESSAGE BELOW AND TERMINATE: 
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Thank you for your interest; however, either your profile does not meet our study’s needs for this 
particular study, or we have already filled our quota of respondents who match your profile. We still 
value your opinion and will contact you in the future with opportunities to complete another study. 
FOR RESPONDENTS WHO QUALIFY, SHOW THE FOLLOWING MESSAGE: 
Doctor, you meet the criteria for inclusion in our study. The focus of this study is to understand the 
treatment of mental health disorders in children less than 18 years of age. The remainder of this study 
will deal with the issues in this treatment area.  
 
11. PATIENT SIMULATION: 
 
• EACH RESPONDENT WILL BE RANDOMLY ASSIGNED TO 1 OF 3 PATIENT PROFILE SETS. 
• EACH PROFILE SET SHOULD BE USED THE SAME NUMBER OF TIMES WITHIN EACH 
SPECIALTY TYPE. 
• RESPONDENTS WILL BE SHOWN THE 10 PATIENT PROFILES IN THE ASSIGNED SET. 
• THE LAYOUT FOR PATIENT ATTRIBUTE TEXT FIELDS IS GIVEN BELOW.  SAMPLE PATIENT 
PROFILE INCLUDED SEPARATELY. 
On the following screens, you will be presented 10 patients whom you might see in your practice.  
Patients will be presented one at a time.  At the bottom of each patient profile screen, you will be 
asked to indicate your treatment choice for the patient at this time. Please read each patient's 
information carefully and select all of the treatment options you would use with the patient at this 
time.   
For each patient please assume the following: 
• The required work up to support the diagnosis has been completed. 
• The patient has insurance coverage that will cover all of the treatment options listed. 
• Prior authorization will be required for any antipsychotic prescribed for these patients. 
PRESENT 10 PATIENT PROFILES AND RECORD PT_ID AND ALL TREATMENT RESPONSES 
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PT_NAME 
INTRO1  INTRO2 
Demographics Lab values Symptoms 
X1 
  
X2 
X3 
X4 
X5 
 
X6 
X7 
 
X8 
 
X9 
 
X10 
X11 
• X12 
• X13 
• X14 
 
 
S1  S2  S3   
S4 
• S5 
• S6 
• S7 
 
Treatment options:  (Please check all that apply) 
 
Atypical Antipsychotics 
 
 Aripiprazole (Abilify®) 
 Asenapine (Saphiris®) 
 Clozapine (Clozaril®, generic) 
 Iloperidone (Fanapt®) 
 Lurasidone (Latuda®) 
 Olanzapine (Zyprexa®, Zyprexa Relprevv®, generic) 
 Olanzapine & Fluoxetine (Symbyax®, generic) 
 Paliperidone (Invega®, Invega Sustena®) 
 Quetiapine (Seroquel®, Seroquel XR®, generic) 
 Risperidone (Risperidal, Risperidal Consta®, 
generic) 
 Ziprasidone (Geodon®, generic) 
 
Conventional Antipsychotics 
      Perphenazine (Trilafon®, generic) 
      Chlorpromazine (generic) 
      Others 
 
Anti-convulsants 
       Lithium (Lithobid®, generic) 
       Alpha agonists 
       Other 
 
 Anti-depressants 
 Anxiolytics 
 Mood stabilizers 
 Stimulants 
 Other (Please specify ______) 
 Psychosocial Intervention 
 Refer to another physician with experience in 
dealing with pediatric mental health 
 Refer to non-medical practitioner 
 Other non-pharmaceutical treatment 
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FOLLOW UP:   
12. For each of the atypical antipsychotics listed below, please indicate the level of evidence supporting 
use in treating PSYCHOSIS within each of the following age groups: 
For purposes of this question: 
‘Labeled indication’ means that the use of the given drug in the given age group for psychosis is an 
FDA-approved indication. 
‘Medically accepted use but not a labeled indication’ means that the use of the given drug in the 
given age group for psychosis is not an FDA-approved indication, but there is considerable evidence 
supporting its use. 
‘No evidence supporting use’ means that the use of the given drug in the given age group for 
psychosis is not supported by any evidence.  
If you are not familiar with a drug’s indications, you can pick ‘Don’t Know.’ 
 
Product Age  1 2 3 4 
 (years) Labeled 
indication 
Medically 
accepted use 
but not a 
labeled 
indication 
No evidence 
supporting 
use 
Don’t 
Know 
Aripiprazole (Abilify®) 
5 & under     
6 – 12     
13 - 17     
Asenapine (Saphiris®) 
5 & under     
6 – 12     
13 - 17     
Clozapine (Clozaril®) 
5 & under     
6 – 12     
13 - 17     
Iloperidone (Fanapt®) 
5 & under     
6 – 12     
13 - 17     
Lurasidone (Latuda®) 
5 & under     
6 – 12     
13 - 17     
Olanzapine (Zyprexa®) 
5 & under     
6 – 12     
13 - 17     
Olanzapine & Fluoxetine 
(Symbyax®) 
5 & under     
6 – 12     
13 - 17     
Paliperidone (Invega®) 
5 & under     
6 – 12     
13 - 17     
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Quetiapine (Seroquel®) 
5 & under     
6 – 12     
13 - 17     
Risperidone (Risperidal®) 
5 & under     
6 – 12     
13 - 17     
Ziprasidone (Geodon®) 
5 & under     
6 – 12     
13 - 17     
 
 
 
13. EVIDENCE BASED PRACTICE ATTITUDE SCALE: 
The following questions ask about your feelings about using new types of therapy, interventions, or 
treatments.  
Manualized therapy, treatment, or intervention refers to any intervention that has specific guidelines 
and/or components that are outlined in a manual and/or that are to be followed in a structured or 
predetermined way. Indicate the extent to which you agree with each item using the following scale: 
Statement 0 1 2 3 4 
 Not at 
all 
To a 
slight 
extent 
To a  
moderate 
extent 
To a 
great 
extent 
To a very 
great 
extent 
I like to use new types of 
therapy/interventions to help my clients. 
 
     
I am willing to try new types of  
therapy/interventions even if I have to follow 
a treatment manual 
 
     
I know better than academic researchers 
how to care for my clients. 
 
     
I am willing to use new and different types of 
therapy/interventions developed by 
researchers. 
 
     
Research based treatments/interventions 
are not clinically useful. 
 
     
Clinical experience is more important than 
using manualized therapy/interventions      
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I would not use manualized 
therapy/interventions. 
 
     
I would try a new therapy/intervention even 
if it were very different from what I am used 
to doing 
     
 
14. For the following statements: 
If you received training in a therapy or intervention that was new to you, how likely would you be to 
adopt it if: 
Statement 0 1 2 3 4 
 Not at 
all 
To a slight 
extent 
To a  
moderate 
extent 
To a 
great 
extent 
To a very 
great 
extent 
it was intuitively appealing? 
      
it “made sense” to you? 
      
it was required by your supervisor? 
      
it was required by your agency? 
      
it was required by your state? 
      
it was being used by colleagues who were 
happy with it? 
 
     
you felt you had enough training to use it 
correctly? 
 
     
 
 
 
15. Now please think about the decisions you have to make when selecting treatments for patients 
with psychosis.  For each of the following treatment attributes, please rate how well you think 
each of the listed products performs.   
 
Please rate each product on each attribute using a 7-point scale where 1 = “Performs poorly on the 
attribute” and 7 = “Performs very well on the attribute.”   If you are not familiar enough with a product 
to rate it on a goal, please enter a “0” 
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For most respondents, it is easier to do the ratings across each row. 
ROTATE/RANDOMIZE PRESENTATION ORDER OF PRODUCTS AND ATTRIBUTES 
  
Abilify 
(aripiprazole) 
Geodon 
(ziprasidone
) 
Risperdal 
(risperidone) 
Seroquel/Seroque
l XR (quetiapine) 
Zyprexa 
(olanzapine
) 
a. Efficacy – Positive 
Symptoms 
          
b. Efficacy – Negative 
Symptoms 
          
c. Efficacy –Risk of 
suicide 
 
          
d. Dosing/titration           
e. Side Effect – 
Cognitive 
Impairment 
 
     
f. Side Effect – 
Metabolic syndrome 
          
g. Side Effect – QT 
prolongation 
          
h. Side Effect – 
Sexual side effects 
          
i. Side Effect – 
Weight Gain 
          
j.  Side Effect- Extra 
Pyramidal Symptoms 
          
k. Cost to patient           
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PHYSICIAN BACKGROUND: Please answer the following questions about yourself. 
16. What is your age?  _____ 
 
17. What is your gender? 
(1) Male 
(2) Female 
 
18. Which race or ethnicity do you most identify?  
(1) White (non-Hispanic) 
(2) Black or African American (non-Hispanic) 
(3) Hispanic or Latino/a (Black or White) 
(4) American Indian or Alaska Native 
(5) Asian American 
(6) Native Hawaiian or Other Pacific Islander 
(7) Other 
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